Market closed
Travere Therapeutics/$TVTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Travere Therapeutics
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Ticker
$TVTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
380
Website
TVTX Metrics
BasicAdvanced
$1.4B
Market cap
-
P/E ratio
-$4.55
EPS
0.70
Beta
-
Dividend rate
Price and volume
Market cap
$1.4B
Beta
0.7
52-week high
$17.76
52-week low
$5.12
Average daily volume
2M
Financial strength
Current ratio
1.709
Quick ratio
1.592
Long term debt to equity
-1,078.801
Total debt to equity
-1,321.449
Interest coverage (TTM)
-25.00%
Management effectiveness
Return on assets (TTM)
-26.14%
Return on equity (TTM)
-279.94%
Valuation
Price to revenue (TTM)
6.567
Price to book
-44.26
Price to tangible book (TTM)
-10.01
Price to free cash flow (TTM)
-3.617
Growth
Revenue change (TTM)
57.08%
Earnings per share change (TTM)
272.21%
3-year revenue growth (CAGR)
-2.75%
3-year earnings per share growth (CAGR)
1.36%
What the Analysts think about TVTX
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Travere Therapeutics stock.
TVTX Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TVTX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TVTX News
AllArticlesVideos
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
GlobeNewsWire·9 hours ago
Travere Therapeutics Announces Proposed Public Offering of Common Stock
GlobeNewsWire·14 hours ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
Accesswire·4 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Travere Therapeutics stock?
Travere Therapeutics (TVTX) has a market cap of $1.4B as of November 08, 2024.
What is the P/E ratio for Travere Therapeutics stock?
The price to earnings (P/E) ratio for Travere Therapeutics (TVTX) stock is 0 as of November 08, 2024.
Does Travere Therapeutics stock pay dividends?
No, Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Travere Therapeutics dividend payment date?
Travere Therapeutics (TVTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Travere Therapeutics?
Travere Therapeutics (TVTX) has a beta rating of 0.7. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.